|
2024 Conference Publication Risk of Infection After Acute Severe Ulcerative Colitis in East Asia and Australia/New Zealand: AOCC and ANZIBDC collaboration studyKim, S. J., Kim, D. H., Park, S. H., Kim, K. O., Lee, Y. J., Song, E. M., Kim, E. S., Lee, H. S., An, Y. K., Begun, J., Ruddick-Collins, L., Fernandes, R., Liu, J., Cao, Q., Kobayashi, T. and Wei, S. C. (2024). Risk of Infection After Acute Severe Ulcerative Colitis in East Asia and Australia/New Zealand: AOCC and ANZIBDC collaboration study. 19th Congress of ECCO, Stockholm, Sweden, 21-24 February 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjad212.0892 |
|
2024 Conference Publication Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitisKhoo, E., Amiss, A., Ding, J. N., Bryant, R., Mohsen, W., Connor, S., Leung, R., Croft, A., Lynch, K., Sparrow, M., De Cruz, P., An, Y. K., Holtmann, G. and Begun, J. (2024). Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitis. 19th Congress of ECCO, Stockholm, Sweden, 21-24 February 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjad212.0984 |
|
2024 Conference Publication Upadacitinib is safe and effective in Ulcerative Colitis patients with prior exposure to TofacitinibGilmore, R., Fernandes, R., Hartley, I., Arzivian, A., Leong, R., Andrew, B., Vasudevan, A., Greeve, T., Moore, G., Kim, S., Lightowler, D., Singh, A., Mahy, G., Mithanthaya, A., Venugpal, K., Han, S., Bryant, R., West, J., Segal, J., Christensen, B., Ding, N. J., An, Y. K. and Begun, J. (2024). Upadacitinib is safe and effective in Ulcerative Colitis patients with prior exposure to Tofacitinib. 19th Congress of ECCO, Stockholm, Sweden, 21-24 February 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjad212.1194 |
|
2024 Conference Publication Peripheral immune cell activity and biopsy gene expression in chronic pouchitis patients treated with tofacitinib: early induction results from the STOPit trialDavies, J., Amiss, A., Khoo, E., An, Y. K. and Begun, J. (2024). Peripheral immune cell activity and biopsy gene expression in chronic pouchitis patients treated with tofacitinib: early induction results from the STOPit trial. 19th Congress of ECCO, Stockholm, Sweden, 21-24 February 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjad212.0164 |
|
2024 Conference Publication Clinical Characteristics of Steroid-Dependent Ulcerative Colitis Patients after Acute Severe Ulcerative Colitis Treatment in East Asia and Australia/New Zealand: AOCC and ANZIBDC collaboration studyKim, D. H., Park, S. H., Kim, H. S., Kim, S. J., Kim, K. O., Lee, Y. J., Song, E. M., Kim, E. S., Lee, H. S., An, Y. K., Begun, J., Ruddick-Collins, L., Fernandes, R., Liu, J., Cao, Q., Kobayashi, T. and Wei, S. C. (2024). Clinical Characteristics of Steroid-Dependent Ulcerative Colitis Patients after Acute Severe Ulcerative Colitis Treatment in East Asia and Australia/New Zealand: AOCC and ANZIBDC collaboration study. 19th Congress of ECCO, Stockholm, Sweden, 21-24 February 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjad212.0555 |
|
2024 Conference Publication PREDICT UC: Optimising Infliximab Induction therapy for Acute Severe Ulcerative Colitis - A Randomised Controlled TrialChoy, M., Suen, C. F. D. Li Wai, Con, D., Boyd, K., Pena, R., Burrell, K., Rosella, O., Proud, D., Brouwer, R., Gorelik, A., Liew, D., Connell, W., Wright, E., Taylor, K., Pudipeddi, A., Sawers, M., Christensen, B., Ng, W., Begun, J., Radford-Smith, G., Garg, M., Martin, N., Van Langenberg, D. R., Ding, N. S., Beswick, L., Leong, R. W., Sparrow, M. P. and De Cruz, P. (2024). PREDICT UC: Optimising Infliximab Induction therapy for Acute Severe Ulcerative Colitis - A Randomised Controlled Trial. 19th Congress of ECCO Stockholm, Stockholm, Sweden, 21-24 February 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjad212.1002 |
|
2024 Journal Article Cannabidiol - help and hype in targeting mucosal diseasesMoniruzzaman, Md, Janjua, Taskeen Iqbal, Martin, Jennifer H., Begun, Jakob and Popat, Amirali (2024). Cannabidiol - help and hype in targeting mucosal diseases. Journal of Controlled Release, 365, 530-543. doi: 10.1016/j.jconrel.2023.11.010 |
|
2024 Conference Publication A cost-effective Inflammatory Bowel Disease flare management pathway utilising rapid access intestinal ultrasound and nurse-led triage to achieve hospital avoidance with increased patient satisfactionFernandes, R., Khoo, E., Harris, H., Gilmore, R., Khaing, M., Begun, J., An, Y. K. and Mater IBD Research Group (2024). A cost-effective Inflammatory Bowel Disease flare management pathway utilising rapid access intestinal ultrasound and nurse-led triage to achieve hospital avoidance with increased patient satisfaction. 19th Congress of ECCO, Stockholm, Sweden, 21-24 February 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjad212.0750 |
|
2024 Conference Publication The real-world use of five-aminosalicylate (5ASA) treatment for Ulcerative Colitis in Australia and New Zealand: Crohn's Colitis Cure (CCC) data insight's programPipicella, J. L., McNamara, J., Wilson, W., Lynch, K., Walker, G., Begun, J., Lawrance,, Ghaly, S., Radford-Smith, G., Williams, A. J., Gearry, R., Schultz, M., Brett, L., Andrews, J. M. and Connor, S. J. (2024). The real-world use of five-aminosalicylate (5ASA) treatment for Ulcerative Colitis in Australia and New Zealand: Crohn's Colitis Cure (CCC) data insight's program. 19th Congress of ECCO Stockholm, Stockholm, Sweden, 21-24 February 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjad212.1010 |
|
2023 Journal Article Comprehensive systematic review and pooled analysis of real‐world studies evaluating immunomodulator and biologic therapies for chronic pouchitis treatmentKhoo, Emi, Lee, Andrew, Neeman, Teresa, An, Yoon‐Kyo and Begun, Jakob (2023). Comprehensive systematic review and pooled analysis of real‐world studies evaluating immunomodulator and biologic therapies for chronic pouchitis treatment. JGH Open, 7 (12), 899-907. doi: 10.1002/jgh3.13000 |
|
2023 Journal Article Guselkumab in patients with moderately to severely active ulcerative colitis: QUASAR phase 2b induction studyPeyrin-Biroulet, Laurent, Allegretti, Jessica R., Rubin, David T., Bressler, Brian, Germinaro, Matthew, Huang, Kuan-Hsiang (Gary), Shipitofsky, Nicole, Zhang, Hongyan, Wilson, Rebbecca, Han, Chenglong, Feagan, Brian G., Sandborn, William J., Panés, Julian, Hisamatsu, Tadakazu, Lichtenstein, Gary R., Sands, Bruce E., Dignass, Axel, Abrahamovych, Orest, Afanasieva, Halyna, Aitova, Lilia, Altintas, Engin, Altwegg, Romain, Andreev, Pavel, Aomatsu, Kazuki, Augustyn, Monika, Balestrieri, Paola, Begun, Jakob, Brunatto, Luciana, Bulgheroni, Diego ... QUASAR Study Group (2023). Guselkumab in patients with moderately to severely active ulcerative colitis: QUASAR phase 2b induction study. Gastroenterology, 165 (6), 1443-1457. doi: 10.1053/j.gastro.2023.08.038 |
|
2023 Journal Article Pre-existing tissue mechanical hypertension at adherens junctions disrupts apoptotic extrusion in epitheliaMann, Zoya, Lim, Fayth, Verma, Suzie, Nanavati, Bageshri N., Davies, Julie M., Begun, Jakob, Hardeman, Edna C., Gunning, Peter W., Subramanyam, Deepa, Yap, Alpha S. and Duszyc, Kinga (2023). Pre-existing tissue mechanical hypertension at adherens junctions disrupts apoptotic extrusion in epithelia. Molecular Biology of the Cell, 35 (1) br3, 1-12. doi: 10.1091/mbc.e23-08-0337 |
|
2023 Conference Publication Goblet cell specific anti-apoptotic role of interleukin-24 in spondyloarthritis-associated ileitisCameron, Amy, Giri, Rabina, Begun, Jakob, Wells, Timothy, Thomas, Ranjeny and Bergot, Anne-Sophie (2023). Goblet cell specific anti-apoptotic role of interleukin-24 in spondyloarthritis-associated ileitis. ACR Convergence 2023, San Diego, CA, United States, 10 - 15 November 2023. Hoboken, NJ, United States: John Wiley & Sons. |
|
2023 Conference Publication Real-world study finds similar effectiveness of biologics but higher durability of ustekinumab in patients with Crohn's disease: Preliminary results from the COMPARE-IT Crohn's disease studyEtchegaray, A., Fernandes, R., Anandan, A. Shanmuga, Selvanathan, P., Malloy, R., Gilmore, R., Pham, H., Begun, J. and An, Y-K (2023). Real-world study finds similar effectiveness of biologics but higher durability of ustekinumab in patients with Crohn's disease: Preliminary results from the COMPARE-IT Crohn's disease study. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons. |
|
2023 Conference Publication Reducing hospital resource utilization and improving patient satisfaction with an innovative inflammatory bowel disease nurse-led clinical care pathway with rapid-access intestinal ultrasoundFernandes, R., Harris, H., Khoo, E., Gilmore, R., Howlett, M., Walker, N., Hendy, P., Begun, J. and An, Y-K (2023). Reducing hospital resource utilization and improving patient satisfaction with an innovative inflammatory bowel disease nurse-led clinical care pathway with rapid-access intestinal ultrasound. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons. |
|
2023 Conference Publication Vedolizumab has longer persistence than infliximab for ulcerative colitis in a real-world cohort study: Preliminary results from the COMPARE-IT studyAnandan, A. Shanmuga, Fernandes, R., Etchegaray, A., Malloy, R., Selvanathan, P., Gilmore, R., Pham, H., Begun, J. and An, Y-K (2023). Vedolizumab has longer persistence than infliximab for ulcerative colitis in a real-world cohort study: Preliminary results from the COMPARE-IT study. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2-5 September 2023. Richmond, VIC Australia: John Wiley & Sons. |
|
2023 Conference Publication Australian consensus on ustekinumab in Crohn's diseaseBegun, J., An, Y-K, Bryant, R., Christensen, B., Leong, R., Studd, C. and Thin, L. (2023). Australian consensus on ustekinumab in Crohn's disease. HOBOKEN: WILEY. |
|
2023 Conference Publication Withdrawal vs continuation of thiopurine in vedolizumab-treated patients with ulcerative colitis (VIEWS): A multicenter randomized controlled trialPudipeddi, A., Paramsothy, S., Kariyawasam, V., Paramsothy, R., Ghaly, S., Haifer, C., An, Y-K, Begun, J., Connor, S., Corte, C., Ward, M., De Cruz, P., Fung, C., Redmond, D., Chan, W., Mourad, F. and Leong, R. (2023). Withdrawal vs continuation of thiopurine in vedolizumab-treated patients with ulcerative colitis (VIEWS): A multicenter randomized controlled trial. HOBOKEN: WILEY. |
|
2023 Conference Publication Durability of escalated anti-tumor necrosis factor (TNF) therapy in Crohn's disease is similar between TNF-naive and TNF-experienced patients and may be improved with proactive drug monitoring: An Australian multicenter experienceGilmore, R., Fernandes, R., Schildkraut, T., Joshi, R., Lin, L., Etchegaray, A., Anandan, A. Shanmuga, Begun, J., An, Y-K and Wright, E. (2023). Durability of escalated anti-tumor necrosis factor (TNF) therapy in Crohn's disease is similar between TNF-naive and TNF-experienced patients and may be improved with proactive drug monitoring: An Australian multicenter experience. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2-5 September 2023. Richmond, VIC Australia: John Wiley & Sons. |
|
2023 Journal Article MUC13 cell surface mucin limits Salmonella Typhimurium infection by protecting the mucosal epithelial barrierMcGuckin, Michael A., Davies, Julie M., Felgner, Pascal, Wong, Kuan Yau, Giri, Rabina, He, Yaowu, Moniruzzaman, Md., Kryza, Thomas, Sajiir, Haressh, Hooper, John D., Florin, Timothy H., Begun, Jakob, Oussalah, Abderrahim, Hasnain, Sumaira Z., Hensel, Michael and Sheng, Yong H. (2023). MUC13 cell surface mucin limits Salmonella Typhimurium infection by protecting the mucosal epithelial barrier. Cellular and Molecular Gastroenterology and Hepatology, 16 (6), 985-1009. doi: 10.1016/j.jcmgh.2023.08.011 |
